MJMichael Patrick Johnston

Michael Patrick Johnston

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Patrick Johnston has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher D. Byrne

    Southampton National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton General Hospital, Southampton, UK

    4 shared publications
  • Janisha Patel

    Department of Hepatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK

    2 shared publications
  • Ryan Buchanan

    Faculty of Medicine University of Southampton Southampton UK

    2 shared publications
  • Alison Sefcick

    Consultant Haematologist, Royal Alexandra Hospital, Paisley, NHS Greater Glasgow and Clyde, Glasgow, UK, nhsggc.org.uk

    1 shared publication
  • Charlotte Cook

    Department of Hepatology, University Hospital Southampton NHS Foundation Trust, Southampton, UK

    1 shared publication
  • Fiona Finlay

    Queen Elizabeth University Hospital, Glasgow Scotland, National Health Service, United Kingdom

    1 shared publication

Latest Publications

  • Open Access

    Transient Unexplained Severe Acute Hyperbilirubinaemia and Cholestasis in a Patient With Hereditary Spherocytosis

    by Jennifer Richardson, Michael Johnston, Alison Sefcick, Karin Oien

    Hereditary spherocytosis is an inherited red cell membrane disorder resulting in haemolytic anaemia. Recognised clinical manifestations include anaemia, jaundice, splenomegaly and gallstones. Here we describe the case of a 40‐year‐old male with hereditary spherocytosis presenting with severe hyperbilirubinaemia. Liver biopsy demonstrated features consistent with acute severe cholestasis. Despite extensive investigations for gallstone disease and other causes of liver pathology, no aetiology was identified. There are very few reports in the literature describing cases of profound unexplained jaundice in hereditary spherocytosis. Hereditary spherocytosis may be associated with idiopathic acute cholestasis. We report that the case was managed conservatively and spontaneously resolved.

  • Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD)

    by Michael P. Johnston, Janisha Patel, Christopher D. Byrne

    : Non-alcoholic fatty liver disease (NAFLD) and alcohol related fatty liver disease (AFLD) both represent a spectrum of liver disease severity from hepatic steatosis to fibrosis and cirrhosis. Both NAFLD and AFLD are common diseases in the general population. NAFLD affects ~25% of the adult global population whilst AFLD has become the commonest indication for liver transplantation in the United States. It is often not possible to distinguish between NAFLD and AFLD on examination of liver histology, consequently, differentiation between NAFLD and AFLD is heavily reliant on a history of alcohol consumption. : Age, smoking, alcohol consumption and sex appear to influence the risk of mortality in NAFLD or AFLD. In NAFLD and AFLD, the key causes of increased liver-related mortality are advanced liver fibrosis and cirrhosis leading to complications such as hepatocellular carcinoma and decompensated cirrhosis. NAFLD and AFLD are also associated with an increased risk of all-cause mortality including an increased risk of extra-hepatic malignancy. Non-invasive biomarkers of liver disease severity in NAFLD and AFLD perform poorly to predict mortality. However, alanine aminotransferase, gamma-glutamyl transpeptidase, FIB-4 and the NAFLD Fibrosis Score are independently associated with increased mortality in NAFLD. : Both NAFLD and AFLD are associated with extra-hepatic risk factors and complications such as metabolic syndrome encompassing obesity, hypertension, type 2 diabetes mellitus, and chronic kidney disease. AFLD is associated with hypertension and cardiovascular disease as well as other organ damage. : This narrative review discusses the associations, risk factors and diagnostic biomarkers linking NAFLD and AFLD with increased mortality.


  • Open Access

    Diabetes is associated with increased risk of hepatocellular carcinoma in non-alcoholic steatohepatitis with cirrhosis—implications for surveillance and future pharmacotherapy

    by Michael P. Johnston, Janisha Patel, Christopher D. Byrne

    Diabetes is associated with increased risk of hepatocellular carcinoma in non-alcoholic steatohepatitis with cirrhosis—implications for surveillance and future pharmacotherapy


  • Reduction of HbA1c in patients with type 2 diabetes following duodenal mucosal resurfacing: could other factors be at play?

    by Michael P Johnston, Ryan Malcolm Buchanan, Janisha Patel, Nadeem Tehami


  • Non‐invasive liver fibrosis scores are strongly associated with liver cancer mortality in general population without liver disease

    by Ki‐Chul Sung, Michael P. Johnston, Mi Yeon Lee, Christopher D. Byrne

    Background & Aims: In a general population without known liver disease, we tested whether: (a) increased liver fibrosis scores (FIB‐4 and APRI) are associated with liver cancer mortality and (b) the probability that a person with a higher score died of liver cancer.Methods: In a retrospective occupational cohort who underwent annual/biennial health examinations (between 2002 and 2015), subjects were excluded with known chronic liver disease. Based on their baseline FIB‐4 and APRI scores, subjects were categorised in low‐/intermediate‐/high‐risk groups for advanced liver fibrosis. Using Cox proportional hazards regression analyses adjusted hazard ratios (aHR) were estimated for liver cancer mortality, with the low‐risk FIB‐4/APRI group as the reference. Harrell's C statistics were also calculated.Results: In 200 479 participants, mean (SD) age was 36.4 (7.7) years. Median follow‐up was 4.1 years (IQR 2.10‐8.03) with 80 liver cancer deaths. High baseline FIB‐4 or APRI scores occurred in 0.25% and 0.09% of subjects respectively. A high FIB‐4 or APRI score was associated with a markedly increased risk of liver cancer mortality (aHRs 629.10 [95% CI 228.74‐1730.20] and 80.42 [95% CI 34.37‐188.18]) respectively. C statistics were FIB‐4 = 0.841 (95% CI 0.735‐0.946) and APRI = 0.933 (95% CI 0.864‐0.999).Conclusions: In a general population without known liver disease, high FIB‐4 or high APRI (in keeping with a high probability of advanced fibrosis) occurred in 0.25% (FIB‐4) and 0.09% (APRI) of subjects. Both scores were associated with a markedly increased risk of liver cancer mortality and FIB‐4 and APRI models both strongly predicted liver cancer mortality.


  • Multi-drug approaches to NASH: what’s in the development pipeline?

    by Michael P Johnston, Janisha Patel, Christopher D Byrne

    Introduction The pandemic of obesity over the last two decades has triggered a rise in prevalence of non-alcoholic fatty liver disease (NAFLD). NAFLD is associated with liver-related- and cardiovascular complications. Despite this, the first licensed drug for NAFLD is yet to be approved. Given the scale of the problem and unmet needs, there is a myriad of agents in the development pipeline. Areas covered We discuss promising agents in early phase clinical trials and categorize these agents based on their action on steatosis, steatohepatitis and fibrosis. Furthermore, given the multisystemic nature of NAFLD, we consider the effects of these agents on the liver, their cardiometabolic effects, and the potential future strategies of combination therapies. Expert opinion The paradigm for the ideal drug is the targeting of both steatohepatitis and fibrosis and the amelioration of cardiometabolic risk factors. New drugs that confer benefit in NASH, must also be tested for their effects on T2DM and CVD. The treatment of NASH will become analogous to the treatment of hypertension; it is very likely that multiple classes of drugs targeting different mechanistic pathways will be necessary because no single agent is likely to control all aspects of this complex liver disease.


  • Fatal Pneumocystis jirovecii pneumonia in a non-immunocompromised patient with alcohol-related liver cirrhosis

    by Nicholas J Hadfield, Subothini Selvendran, Michael P Johnston

    This report presents the fatal case of a 63-year-old man with a new presentation of liver cirrhosis, presumed concurrent acute alcoholic hepatitis and development of Pneumocystis jirovecii pneumonia. The patient had none of the traditional immunosuppressing risk factors associated with Pneumocystis jirovecii pneumonia such as corticosteroid use, haematological malignancy or HIV infection. In the literature, there are two case reports and a case series of two patients which describe the development of Pneumocystis jirovecii pneumonia in acute alcoholic hepatitis. However, all of these previously described cases include identifiable risk factors – namely corticosteroid use and HIV infection. This case suggests that special consideration should be given to Pneumocystis jirovecii pneumonia as a cause of opportunistic infection in acute alcoholic hepatitis.


  • Open Access

    Immunotherapy for hepatocellular carcinoma: Current and future

    by Michael P Johnston, Salim I Khakoo

    Immunotherapy for hepatocellular carcinoma: Current and future


  • Open Access

    PTU-015 Natural history of varices in the era of non-invasive assessment

    by Michael Patrick Johnston, Mark Wright

    Introduction Guidelines recommend endoscopic variceal screening and surveillance in patients with cirrhosis.1 The rate of development of large oesophageal varices needing treatment appears to be 7–8% per year.2,3 However, with a growing proportion of diagnoses also now being made by Fibroscan we hypothesize that this rate may be lower. Methods We performed a case note review of 304 patients with a liver stiffness measurement (LSM) more than 15 kPa on Fibroscan between April 2012 and February 2016. Patients also had to have an endoscopy within 6 months to be included. We excluded patients with previous decompensation, hepatocellular carcinoma, inaccurate LSM (IQR >30%) or LSM felt to be aberrant by the clinician based on clinical, radiological or histological grounds. For patients with hepatitis C (HCV) we used post-SVR LSM. We recorded sex, age, aetiology of liver disease, LSM, platelet count, endoscopic findings at 0–6 months and at 24–48 months, duration of follow-up, incidence of bleeding or death. Varices were documented as absent, small or large. Results 113 patients were included. The most common aetiologies were non-alcoholic fatty liver disease (36.2%), alcoholic liver disease (29.3%) and HCV (20.7%). Mean age was 59.3 ± 11.5 years. LSM was 33.4 ± 17.1 kPa. Median follow-up was 4 years. Baseline endoscopy revealed no varices in 76 patients (67.3%), small varices in 29 patients (25.7%) and large varices in 8 patients (7.1%). 6 of the patients (5.3%) had a variceal bleed within 12 months. All large varices underwent band ligation (VBL) as per local practice. 58 patients went on to have a repeat endoscopy at 24–48 months. There was no progression of absent/small varices in 50 patients (86.2%) and a static gastric varix in 1 patient (1.7%). There was progression to large varices in 7 patients (13.8%) including 1 variceal haemorrhage. Conclusions In our group of patients with compensated cirrhosis the rate of development of clinically significant varices over 3 years appears to be lower than previous estimates. Weaknesses of the study include its retrospective nature and drop out rate. However, the findings would fit with our perception of an increased rate of diagnosis of advanced chronic liver disease by Fibroscan. The natural history of varices may be different to historic populations diagnosed on histological grounds or overt clinical and radiological features. References U.K. Guidelines on the Management of Variceal Haemorrhage in Cirrhotic Patients, Gut ( 2015) 64(11) 1680–1704 R Groszmann, G Garcia-Tsao, J Boschet al, Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis, NEJM ( 2005) 353(21) 2254–2261 M Merli, G Nicolini, S Angeloniet al, Incidence and natural history of small esophageal varices in cirrhotic patients, J Hepatol. ( 2003) 38(3) 266–272